Our results suggest that the dual activation of PPARα and PPARγ by saroglitazar can effectively improve steatosis, fibrosis, and aspects of necro-inflammation in the HF-induced NASH model better than fenofibrate and pioglitazone. Here, PPARA is linked to hydrops fetalis.